Santarus, Inc. (SNTS)
-NasdaqGS 22.77 
0.49(2.20%) 2:24PM EDT - Nasdaq Real Time Price
| Prev Close: | 22.28 |
|---|
| Open: | 21.56 |
|---|
| Bid: | 22.65 x 100 |
|---|
| Ask: | 22.69 x 300 |
|---|
| 1y Target Est: | 22.30 |
|---|
| Beta: | 1.8 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 20.00 - 22.89 |
|---|
| 52wk Range: | 4.82 - 24.00 |
|---|
| Volume: | 1,369,171 |
|---|
| Avg Vol (3m): | 1,341,600 |
|---|
| Market Cap: | 1.48B |
|---|
| P/E (ttm): | 43.97 |
|---|
| EPS (ttm): | 0.52 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Ironwood Pharma Prices Stock OfferingZacks(Thu 11:35AM EDT)
- The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Santarus and Jazz PharmaceuticalsZacks(Thu 8:01AM EDT)
- Bull of the Day: Santarusat Seeking Alpha(Wed, May 22)
- Data on Merck KGaA's L-BLP25Zacks(Wed, May 22)
- Data on UCB's NeuproZacks(Wed, May 22)
- XenoPort Resumes Horizant SupplyZacks(Wed, May 22)
- The Retire Young Portfolio: Time To Add A High-Growth Medicine Companyat Seeking Alpha(Wed, May 22)
- Sanofi/REGN's Dupilumab Data PublishedZacks(Wed, May 22)
- FDA Designation for Synageva CandidateZacks(Wed, May 22)
- Swiss Issue for AMAG/Takeda's RiensoZacks(Wed, May 22)
- Additional Patent for Acorda's AmpyraZacks(Wed, May 22)
- Generic Launches at Mylan ContinueZacks(Wed, May 22)
- Stocks Climb In Mixed Trade; Toll Bros. Up, Target Slumpsat Investor's Business Daily(Wed, May 22)
- AbbVie Extends Galapagos DealZacks(Wed, May 22)
- Santarus Is a Real Gas!at Motley Fool(Wed, May 22)
Key Statistics
| Forward P/E (1 yr): | 17.59 |
|---|
| P/S (ttm): | 5.75 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.88 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.17 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | 1.17 |
|---|
Business Summary
Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists.
View More